Shanghai, China

John L Xu

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Mab-Venture Biopharm Co., Ltd.. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of John L. Xu in Antibody Development

Introduction

John L. Xu is an accomplished inventor based in Shanghai, China, known for his significant contributions to the field of biopharmaceuticals. With a strong focus on immunology, Xu has made strides in the development of antibodies, which are crucial for therapeutic interventions in various diseases.

Latest Patents

John L. Xu holds a patent for the "Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof." This innovative invention involves an antibody that binds to lymphocyte activation gene-3 (LAG-3), showcasing its potential applications in treating immune-related conditions.

Career Highlights

Currently, John L. Xu works at Mab-venture Biopharm Co., Ltd., a company dedicated to developing advanced biopharmaceutical products. His experience and expertise in antibody development have positioned him as a leading figure in his field.

Collaborations

Throughout his career, Xu has collaborated with notable professionals in the industry, including Shaoxiong Wang and Jing Zhao. These collaborations have contributed to the advancements in research and the successful development of innovative therapeutic solutions.

Conclusion

John L. Xu's work and patent in the field of antibody research reflect his dedication to addressing critical health challenges. As he continues to innovate within the biopharmaceutical industry, his contributions will undoubtedly play a pivotal role in the advancement of medical science and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…